CDMO Nucleotide API
High-quality nucleotide API manufacturing through NATiAS® collaboration.
End-to-end support from process development to GMP production and analytics.
Comprehensive CDMO for Nucleotide API Development and Manufacture
NAGASE provides contract development and manufacturing organization (CDMO) services for Nucleotide Active Pharmaceutical Ingredients (APIs) through its partnership with NATiAS®, a Japanese CDMO known for proprietary process know-how and competitive cost structures. Capabilities span process development and scale-up, non-GMP and GMP production from small to commercial scale, and full analytical support including method development, validation, and stability studies to meet regulatory expectations.
NAGASE supplies these CDMO solutions globally with technical support and international logistics for pharmaceutical programs worldwide.
Applications
Nucleotide APIs are used across diverse therapeutic and diagnostic workflows in modern drug development.
- Antiviral therapeutics based on nucleoside/nucleotide analogs
- Oncology programs requiring nucleotide-based actives or intermediates
- Diagnostic reagents for molecular assays and kit manufacturing
- Biopharma R&D – lead optimization and preclinical supply
- Clinical and commercial supply of nucleotide API batches
Features
CDMO services combine proprietary process expertise, GMP readiness, and robust analytics for reliable nucleotide API supply.
- Process development & scale-up – Efficient transfer from lab to commercial scale
- GMP/non-GMP flexibility – Small to commercial batches across phases
- Analytical method development – Fit-for-purpose assays for nucleotides
- Validation & stability – Regulatory-aligned qualification and shelf-life data
- Cost-competitive production – Proprietary processes to optimize COGS
Service
・Process Development, Scale up
・non-GMP / GMP Production (small – commercial scale)
・Analytical Method Development, Validation, Stability Study